B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NTLA
Intellia TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+95.5
Score
AI commentary
The post-earnings company update is materially positive on HAELO efficacy, regulatory timing, ATTR enrollment and cash runway [#SEC-8K-2026-08-06]. However, the packet does not establish a clean post-print price reaction or analyst revision trend, and social, options and short-interest data are unavailable. The evidence supports monitoring rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-06eventFDA BLA acceptance watch for lonvo-zHigh impact
Intellia reported positive Phase 3 HAELO data for lonvo-z, including an 87% reduction in attacks versus placebo, and anticipates FDA acceptance of its BLA in the second half of 2026, with a potential U.S. launch in the first half of 2027 [#SEC-8K-2026-08-06].
2026-11-06eventATTR Phase 3 restart and enrollment progressHigh impact
Enrollment was reinitiated in nex-z Phase 3 trials, with MAGNITUDE-2 enrollment expected to complete in the second half of 2026. This restores pipeline optionality but remains a restart-and-execution story [#SEC-8K-2026-08-06].
2027-08-08catalystCash runway supports development and launch preparationHigh impact
Intellia ended Q2 with approximately $628 million in cash, cash equivalents and marketable securities and expects this balance to fund operations at least into 2028, reducing near-term financing pressure [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology